Similar articles

• [Treatment of rheumatic diseases with nabumetone. Results of a study using the drug in 18,046 patients].

  Lemmel EM, Stroehmann I. Lemmel EM, et al. Fortschr Med. 1988 Apr 20;106(12):253-6. Fortschr Med. 1988. PMID: 3260888 German. No abstract available.
• Nabumetone (Relifex)--another NSAID.

  [No authors listed] [No authors listed] Drug Ther Bull. 1988 May 31;26(11):41-3. doi: 10.1136/dtb.26.11.41. Drug Ther Bull. 1988. PMID: 3289871 Review. No abstract available.
• Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.

  Friedel HA, Todd PA. Friedel HA, et al. Drugs. 1988 May;35(5):504-24. doi: 10.2165/00003495-198835050-00002. Drugs. 1988. PMID: 3293969 Review.
• Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.

  Friedel HA, Langtry HD, Buckley MM. Friedel HA, et al. Drugs. 1993 Jan;45(1):131-56. doi: 10.2165/00003495-199345010-00009. Drugs. 1993. PMID: 7680981
• Nabumetone--a new NSAID.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 1992 Apr 17;34(868):38-40. Med Lett Drugs Ther. 1992. PMID: 1556995 No abstract available.